Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GOVX
GOVX logo

GOVX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.990
Open
1.980
VWAP
1.88
Vol
78.59K
Mkt Cap
4.29M
Low
1.815
Amount
147.89K
EV/EBITDA(TTM)
--
Total Shares
2.22M
EV
-717.49K
EV/OCF(TTM)
--
P/S(TTM)
0.33
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Show More

Events Timeline

(ET)
2026-01-09
20:00:00
Geovax Labs Inc Trading Halted, News Pending
select
2025-08-07 (ET)
2025-08-07
14:40:07
HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital
select
2025-06-16 (ET)
2025-06-16
16:41:20
GeoVax Labs files to sell 6.15M common units
select
2025-06-16
10:59:06
GeoVax Labs receives favorable European regulatory guidance supporting GEO-MVA
select

News

Benzinga
4.5
02-13Benzinga
U.S. Stocks Decline in Morning Trade as Inflation Rate Eases
  • Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index falling approximately 0.1% to 49,387.55, indicating a cautious market sentiment regarding economic outlook.
  • Sector Dynamics: Utility stocks gained 1.5%, while communication services stocks fell by 0.6%, reflecting a divergence in market performance across sectors that could influence investors' asset allocation strategies.
  • Earnings Highlights: Advance Auto Parts (NYSE:AAP) reported better-than-expected fourth-quarter results, with earnings per share of $0.86 surpassing the analyst consensus of $0.42, and sales reaching $1.973 billion, demonstrating the company's strong performance in a competitive market.
  • Economic Data: The annual inflation rate eased to 2.4% in January, the lowest level since May, down from 2.7% in the previous month, which may impact the Federal Reserve's monetary policy decisions.
Benzinga
9.5
01-09Benzinga
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
  • Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
  • Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
  • Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
  • Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
Benzinga
4.5
2025-12-19Benzinga
Dow Rises by More Than 200 Points; Conagra Stock Declines Following Q2 Earnings Report
  • U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 200 points, while the NASDAQ and S&P 500 also saw increases of 1.03% and 0.73%, respectively.

  • Sector Movements: Information technology shares increased by 1.6%, while real estate stocks experienced a slight decline of 0.1%.

  • Notable Stock Movements: Conagra Brands Inc. shares fell over 4% despite beating earnings estimates, while Autozi Internet Technology's shares surged 85% following a significant investment announcement.

  • Global Market Trends: European and Asian markets closed higher, with notable gains in major indices, and U.S. existing home sales rose by 0.5% in November.

SeekingAlpha
8.5
2025-10-17SeekingAlpha
GeoVax Labs Seeks Approval to Offer 11.9 Million Shares of Common Stock for Shareholders
  • Stock Offering Announcement: GeoVax Labs filed to sell 11.9 million shares of common stock for existing holders.

  • Preliminary Prospectus Note: The filing is a preliminary prospectus and does not constitute an offer to sell.

Globenewswire
1.0
2025-09-23Globenewswire
Live Stream Registration Now Open for Day 2 of the Emerging Growth Conference 86 on September 25
  • Emerging Growth Conference Announcement: The 86th Emerging Growth Conference is scheduled for September 24 & 25, 2025, focusing on companies with strong management and growth potential across various sectors.

  • Keynote Speakers and Schedule: The conference features multiple keynote speakers from various companies, including Kneat.com, Zapp Electric Vehicles, and Citizens, Inc., with sessions conducted via video webcasts.

Globenewswire
1.0
2025-08-18Globenewswire
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open
  • Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.

  • Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.

  • Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.

  • Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.

Wall Street analysts forecast GOVX stock price to rise
2 Analyst Rating
Wall Street analysts forecast GOVX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
10.00
Averages
12.00
High
14.00
Current: 0.000
sliders
Low
10.00
Averages
12.00
High
14.00
D. Boral Capital
Jason Kolbert
Buy -> Hold
downgrade
AI Analysis
2026-02-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2026-02-19
downgrade
Buy -> Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded GeoVax Labs to Hold from Buy without a price target. The firm says the company is facing a "more constrained" near-term outlook with limited catalysts and tightening capital resources. While the company continues to advance GEO-MVA as a potential diversification solution within the mpox vaccine landscape, its near-term execution risk is elevated, the analyst tells investors in a research note.
Roth Capital
Jonathan Aschoff
Buy
maintain
$14
2025-12-26
Reason
Roth Capital
Jonathan Aschoff
Price Target
$14
2025-12-26
maintain
Buy
Reason
Roth Capital analyst Jonathan Aschoff contends that December was "a strong month" GeoVax Labs, citing the EMA issuing formal Scientific Advice affirming that the company's proposed nonclinical package is acceptable, three peer-reviewed publications highlighting clinical and preclinical data for GEO-CM04S1 and Gedeptin, and two U.S. patents being either allowed or issued. The firm has a Buy rating and $14 price target on GeoVax shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GOVX
Unlock Now

Valuation Metrics

The current forward P/E ratio for GeoVax Labs Inc (GOVX.O) is -0.14, compared to its 5-year average forward P/E of -1.45. For a more detailed relative valuation and DCF analysis to assess GeoVax Labs Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.45
Current PE
-0.14
Overvalued PE
-0.19
Undervalued PE
-2.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.51
Undervalued EV/EBITDA
-3.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
53.79
Current PS
0.00
Overvalued PS
172.91
Undervalued PS
-65.32

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

3 stocks with RSI below 25
Intellectia · 221 candidates
Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
WIX logo
WIX
Wix.Com Ltd
4.37B
SOAR logo
SOAR
Volato Group Inc
3.65M
OTLK logo
OTLK
Outlook Therapeutics Inc
32.44M
JTAI logo
JTAI
Jet.AI Inc
5.42M
SPRC logo
SPRC
Scisparc Ltd
4.57M
IPW logo
IPW
iPower Inc
5.62M
RSI below 30 and MACD turning Bullish
Intellectia · 8 candidates
Rsi 14: 0 - 30Moving Average Relationship: PriceCrossAboveMA5
Ticker
Name
Market Cap$
top bottom
CORT logo
CORT
Corcept Therapeutics Inc
3.82B
ELME logo
ELME
Elme Communities
280.35M
OSG logo
OSG
Octave Specialty Group Inc
276.45M
PSTV logo
PSTV
Plus Therapeutics Inc
52.05M
ATRA logo
ATRA
Atara Biotherapeutics Inc
33.17M
APLT logo
APLT
Applied Therapeutics Inc
14.63M

Whales Holding GOVX

L
L1 Capital Pty. Limited
Holding
GOVX
+18.67%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GeoVax Labs Inc (GOVX) stock price today?

The current price of GOVX is 1.84 USD — it has decreased -4.66

What is GeoVax Labs Inc (GOVX)'s business?

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

What is the price predicton of GOVX Stock?

Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GeoVax Labs Inc (GOVX)'s revenue for the last quarter?

GeoVax Labs Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is GeoVax Labs Inc (GOVX)'s earnings per share (EPS) for the last quarter?

GeoVax Labs Inc. EPS for the last quarter amounts to -7.79 USD, decreased -65.68

How many employees does GeoVax Labs Inc (GOVX). have?

GeoVax Labs Inc (GOVX) has 17 emplpoyees as of March 11 2026.

What is GeoVax Labs Inc (GOVX) market cap?

Today GOVX has the market capitalization of 4.29M USD.